A review.Iron supplementation is the standard therapy for patients with uremia requiring renal replacement therapy.In peritoneal dialysis patients, i.v. infused iron diffuses into the peritoneal cavity and induces i.p. inflammation.We evaluated the potential role of DHMEQ on the iron isomaltoside 1000 - Monover (IIS) induced changes in the functional properties of human peritoneal mesothelial cells (MC) in vitro.This study was approved by the Bioethical Committee of the University of Medical Sciences, Poznan, Poland.MC were cultured in medium M199 with hydrocortisone (1μg/mL), antibiotics (streptomycin 100μg/mL and penicillin 100 U/mL), and 10% fetal calf serum (FCS).At the end of the incubation period, supernatants were collected to measure MC secretory activity.He levels of the following substances were measured using ELISA (DuoSet Immunoassay; R&D Systems, Minneapolis, MN): interleukin 6 (IL6), tissue plasminogen activator (tPA), plasminogen acti-vator inhibitor-1 (PAI-1), and transforming growth factor-β1 (TGFβ1).